[5] and were recently validated [6] . In this review, we pholipid antibody syndrome. The antiphosphospholipid antiprovide an overview of the mechanism of thrombosis in body syndrome (APS) describes a clinical entity with recurrent APS, the spectrum of renal abnormalities encountered thrombosis, fetal loss, thrombocytopenia in the presence of with this syndrome, and the available treatment options. lupus anticoagulant and/or antibodies to cardiolipin. These antibodies may be associated with connective tissue diseases such as systemic lupus erythematosus (secondary APS) or be found
BIOLOGY OF ANTIPHOSPHOSPHOLIPID
in isolation (primary APS). Renal syndromes increasingly being reported in association with these antibodies include throm- vated protein C inactivates factors Va and factor VIIIa in the presence of phospholipids and factor S, thus inhibiting the generation of thrombin [7] . APA include It has been more than 15 years since Harris, Hughes and others described the clinical features of the antiphoslupus anticoagulant and anticardiolipin antibodies. The pholipid antibody syndrome (APS) [1] [2] [3] . Since then, lupus anticoagulant is detected in coagulation assays as the syndrome originally scorned as a "black swan" or a it slows the rate of thrombin generation by perturbing laboratory error has evolved as a distinct clinical entity interactions that require phospholipid, thus acting as an [4] that is associated with protean clinical manifestations anticoagulant. The clue to the presence of a lupus anticosuch as arterial and venous thrombosis, recurrent aboragulant is often an increased partial thromboplastin time tions, and thrombocytopenia. Renal manifestations of (PTT) that fails to correct on mixing studies with normal this syndrome have recently received more attention as plasma. The anticardiolipin antibodies, in contrast, are the kidney appears to be a major target organ in both recognized by the ability to bind anionic phospholipids primary and secondary APS. Although more prevalent in solid-phase immunoassays. Thus, anticardiolipin and in patients with systemic lupus erythematosus (SLE), lupus anticoagulant are distinct but complementary tests antiphospolipid antibodies (APAs) occur in patients for APAs. The genesis of APAs may involve both autowithout other manifestations of autoimmune disease, the immune and alloimmune reactions. Alloimmune APAs so-called "primary" APS. The preliminary classification may be observed following an infection such as hepatitis and criteria for diagnosis of APS were published in 1999 C, Lyme disease [8-10], human immunodeficiency virus infection (HIV), or in association with lymphoproliferative disease, and appear to have a weaker association coagulability. Vascular thrombosis represents the clinical hallmark of APS and both arteries and veins may be  2002 by the International Society of Nephrology affected. Thrombosis may affect deep leg veins, as well major platelet membrane glycoproteins [19, 20] . The anti-platelet effects of APAs have been suggested to be as those of the skin, lungs, kidney, central nervous system, and placenta. Thrombocytopenia is quite common.
ANTIBODIES
analogous to that observed in heparin-induced thrombocytopenia [20] , as ␤2-GPI binds to exposed anionic phosWhile the association between these APAs and thrombosis is now well established, the unresolved central issue pholipids on the surface of activated platelets. Platelets circulate in an increased state of activation in APS, but in both primary and secondary APS is how antibodies against phospholipids lead to increased tendency to it is unclear if this is a cause or effect of thrombosis. APAs also show substantial reactivity against endothethrombosis. In the case of lupus anticoagulant, this effect appears paradoxical since an anticoagulant would be exlial cells.
[21] In vitro data suggest that this reactivity of APAs against endothelial cells involves both ␤2-GPIpected to cause bleeding, not thrombosis. Phospholipiddependent coagulation reactions include the following dependent and independent mechanisms. Since virtually any of the biologic processes that involve or require reactions: (1) tissue factor-factor VII (VIIa) mediated activation of factors X and IX; (2) factor IXa and factor phospholipids may be affected by the presence of antibodies that bind to the phospholipids (either directly or VIIIa activation of factor X to factor Xa; and (3) factor Xa and factor Va activation of prothrombin to thrombin via cofactors), any proposed APA-mediated effect based on in vitro studies must be evaluated for in vivo rele-(see Fig. 1 ). The lupus anticoagulant appears to act by limiting the amount of phospholipid available to support vance. Some of these effects are discussed below and summarized in Table 1 . these reactions, and thus prolonging the coagulation times. A major advance in the understanding the thrombophilic effect of these antibodies occurred when two
PATHOGENESIS OF THROMBOSIS IN APS groups led by McNeil et al [11] and Galli et al [12]
The precise mechanism by which the presence of independently observed that the major antigen (cofacAPAs induces thrombosis is not completely understood. tor) for APA is a plasma protein, apolipoprotein H, or Experimental and human data suggest that thrombosis ␤2-GP1. This protein, a glycosylated single-chain plasma induced by APAs may involve changes at the following protein composed of 326 amino acids with a molecular sites: (1) dysregulation of coagulation; (2) platelet actiweight of 50 kD, is a weak anticoagulant that binds to vation; or (3) endothelial injury, disordered transmemanionic phospholipids and inhibits the contact phase of brane signaling, and microvasculopathy. These putative coagulation and the activity of platelet prothrombinase.
pathophysiologic changes are summarized in Table 1 . The exact nature of these epitope(s) remains uncertain.
Thus, these antibodies induce a hypercoagulable state, Data from this laboratory however, show that though which meets Virchow's triad for thrombosis (that is, ab-␤2-GPI increases antibody binding to phospholipid, it is normal rheology, tissue injury and abnormal blood connot an absolute prerequisite for binding [13] . Other data stituent(s) for thrombogenesis) [22] . Data from our instisuggest that monoclonal antibodies with lupus anticoagtution have shown that the thrombogenic effects of these ulant activity can increase the binding of ␤2-GPI to phosantibodies are not confined to human APA, but have pholipid [14] . This process then interferes with essential also been shown for antibodies induced in mice [23] . phospholipid-dependent steps in coagulation, especially
There is substantial evidence that endothelial cell injury/ the assembly of the tenase and prothrombinase comactivation plays a role in both in vitro an in vivo models plexes on anionic phospholipids. Consistent tem [17, 24, 28] , platelet activation appears to play a While binding of APAs to platelets appear to be dependent on ␤2-GPI, other autoantibodies react with the central role in arterial thrombosis in APS. Other poten- (1) the tenase complex; (2) the prothrombinase complex; and (3) the protein C activation complexes. Activation of the extrinsic or intrinsic pathway leads to conversion of factor X to Xa. Factor Xa forms a complex with factor Va and prothrombin on a phospholipid template (prothrombinase complex) and this results in thrombin generation from prothrombin. Activated protein C inactivates factor Va and factor VIIIa in the presence of protein S and phospholipids. APAs may affect all the pathways indicated with an asterisk, resulting in a procoagulant effect or in a "lupus anticoagulant effect" (by inhibition of conversion of prothrombin into thrombin). tially thrombogenic effects involve inflammation and hypertension; renal cortical necrosis; thrombotic microangiopathy; progressive chronic renal failure; as well atherosclerosis [29] . Taken together, these experimental data suggest that thrombosis in association with APAs as thrombosis in patients with renal allografts (Table 2) . involves interference with endogenous anticoagulant systems (such as protein C, annexin V, or vascular anticoag-ANTIPHOSPHOLIPID ANTIBODIES ulant alpha), cellular activation (involving platelets, en-IN SLE-ASSOCIATED NEPHRITIS dothelial cells, and leukocytes), persistent activation of Conley and Hartman initially described the presence coagulation system due to tissue factor activation and of lupus anticoagulant in SLE patients in 1952 [30] . Subinhibition of the antithrombin III pathway, as well as sequently, Bowie et al described thrombosis occurring inhibition of fibrinolysis (see Table 1 ).
in patients with circulating anticoagulants in a seminal paper in 1963.
[31] These observations of the association RENAL SYNDROMES IN APS of APA with glomerular and arterial thrombosis in SLE were extended over the next two decades by Kant et al, The kidney manifestations of APS may result from thrombosis occurring at any location within the renal who reported a strong association between the presence of lupus anticoagulant and the presence of glomerular vasculature, that is, in the renal artery trunk or branches, intra-parenchymal arteries and arterioles, glomerular thrombi in renal biopsy specimens systematically performed in SLE patients seropositive for lupus anticoagucapillaries, and the renal veins. The resulting clinical syndromes consists of variable degrees of proteinuria; lant [32] . While the precise origin of APAs in SLE is unclear, their presence appears to consistently correlate exacerbation of SLE nephropathy; acute renal failure; systemic hypertension, ranging from mild to accelerated with the occurrence of renal thrombotic microangiopa-thy (TMA). It is possible that these antibodies are generpatients, that the presence of anticardiolipin antibody and/or glomerular thrombi portends a worse renal outated by autoimmune responses akin to that which generates anti-nuclear antibodies (ANA). In a meta-analysis come, as patients with APA-positivity had significantly more crescents, more sclerosis, and more glomerular Figure 2 ). This distincpatients with lupus nephritis (45%), but found that the presence of these antibodies per se appeared not to tion is critical as the treatment for each syndrome is different. Aggressive lupus nephritis requires cytotoxic change outcome [38], except for an increased incidence of thrombocytopenia and renal vascular thrombosis.
therapy, whereas APS nephropathy benefits from anticoagulation. The nephropathy of APS occurring in the These thrombotic events involved large arteries and veins as well as the glomerular and intrarenal arteries course of SLE is the most common form of secondary APS. In one study of a cohort of 100 patients with and arterioles. However, the study is limited by the fact that these observations were based on a study of only SLE, APS nephropathy was observed in 63% of patients with APS (abstract; Daugas E et al, J Am Soc Nephrol 18 patients. Previously, Kincaid-Smith et al had reported the occurrence of pregnancy-related acute renal failure 10:A99, 1999). In a recent systematic review of renal biopsies in another 114 patients with SLE, the same investigain 12 women (only two of whom had lupus nephritis) caused by TMA in relation to lupus anticoagulant [36] .
tors studied the lesions of secondary APS nephropathy co-existing with those of lupus nephritis. They found secIt is unclear at present if APA are initiators or accelerators of arterial lesions in TMA, but both roles may ondary APS nephropathy in 36% of this cohort of SLE patients, even though only 22% of their patients had be involved. It should be emphasized that the frequent absence of immunoglobulin deposits in vessels involved APS [47] . This higher proportion of APS nephropathy raises the possibility that renal-limited microvascular disin TMA suggests that thrombosis may be due to mechanisms other than immune-complex disease. In most ease may occur in the course of SLE in some patients. The strengths of this study include a fairly large sample series [38-40], more glomerular thrombi are found in those SLE patients with APAs than those without APAs, size (114 patients), as well as a strict definition criterion for APA. This study also found greater correlation besuggesting an increased morbidity, mostly related to TMA, although these APAs do not affect the World tween lupus anticoagulant positivity and intrarenal thrombosis than was found in patients seropositive for anticarHealth Organization's (WHO) histologic classification. In the same area, it is unclear at this time if these antiboddiolipin antibodies. In addition to the TMA lesions seen acutely in APS nephropathy associated with SLE, other ies affect the response to chemotherapy in lupus nephritis; although microvasular lesions of SLE, in general, lesions such as fibrous intimal hyperplasia, and focal cortical atrophy have also been observed in the affected are considered to be independent risk factors for the progression to end-stage renal disease (ESRD) [41] . An kidneys [47] . An aggressive vasculopathic state with widespread thrombosis called catastrophic antiphospholipid area of on-going controversy relates to the association between the APS-associated lesions (such as glomerular syndrome (CAPS) may also occur in SLE [46, 48] . This syndrome is described in greater detail in the discussion thrombi) and those of lupus nephritis. Miranda et al found no association between the presence of these gloof primary APS below. [47] . The balance of the evidence at this 60], although crescentic glomerulonephritis was observed in one case [63] . Renal involvement in the form time favors the possibility that the occurrence of APS nephropathy in patients with lupus nephropathy may of ARF and/or hematuria has been observed in 14% of a large series of patients with CAPS [59] . TMA may be increase the risk of progression to ESRD, even though the WHO classification is unaffected. In the largest series the initial clinical manifestation of both primary APS and secondary APS. Thus, APS should be considered in published to date [47] , these patients had higher creatinine at time of diagnosis, increased interstitial fibrosis, the differential diagnosis of hemolytic uremic syndrome (HUS), including pospartum cases [65, 66] . It has been and a higher prevalence of hypertension, as discussed later. No study, to our knowledge, has addressed the suggested by some that APAs may be generated in response to thrombosis, rather than being the cause of relative prevalence of both TMA and large-vessel occlusive disease in SLE patients with or without APS.
thrombosis, but the evidence appears to favor a causal role for APAs in the genesis of TMA in this syndrome.
RENAL DISEASE IN PRIMARY APS APA IN SYSTEMIC HYPERTENSION
In contrast to the well-described nephropathy associated with SLE and APS, it was not widely appreciated Hypertension is a common feature of the primary and secondary APS [47, 49] . In the series of primary APS that the primary APS could lead to nephropathy until recently. The studies of the renal lesions in primary APS reported by Nochy et al, hypertension was present in 93% of their patients and was sometimes the only clinical have enabled investigators to observe the lesions due to APS in pure form [47, [49] [50] [51] [52] [53] [54] , without the confounding sign suggestive of nephropathy [49] . In the secondary APS series reported by Kleinknecht et al, all patients effect of co-existing inflammatory changes. Several patients in these reports presented with acute renal failure with SLE and APS had severe hypertension with renal insufficiency [67] . Thus, hypertension appears to be a (ARF). The precise pathogenesis of ARF in the primary APS has not been clearly delineated, but is likely to be marker of nephropathy in both primary and secondary APS. No study to our knowledge has addressed the prevmultifactorial. It may result from TMA, renal cortical necrosis, renal infarction, renal vein thrombosis [55, 56] , alence of APAs in an unselected population of patients with essential hypertension. Hypertension in APS may or in the unique aggressive vasculopathy, CAPS [57] [58] [59] [60] [61] [62] [63] . This is associated with multi-organ failure and wideoften be severe, with some patients presenting with hypertensive emergencies. Rarely, hypertension associated spread thrombotic diathesis. The renal lesions of the primary APS nephropathy are identical to those seen with APS may be associated with microangiopathic hemolytic anemia. It needs to be emphasized that both in other TMAs, including postpartum renal failure and sclerodermal renal crisis, with severe narrowing of the microvasculopathy and/or occlusion of the main trunk of the renal artery can contribute to malignant hyperteninterlobular arteries and afferent arterioles. Predictably, renal ischemia follows these diffuse thromboses. In a sion in the APS. Caccoub et al described five patients with APS complicated by hypertensive crises who all few cases, mesangial IgA deposition has been described [53, 54] . Occasionally, thromboses occur in the large had normal magnetic resonance angiograms of the renal vessels [68] . Three of their patients underwent contrast renal arteries leading to renal infarcts [64] . The urine sediment typically contains few cells or casts, and the angiography, which showed distal microangiopathy, but no stenosis nor thrombosis of the main renal arteries. level of proteinuria varies from mild to nephrotic. The histologic lesions associated with primary APS-related High-dose steroids (prednisone, 1.5 mg/kg/day) and anticoagulation led to rapid resolution of hypertensive crises nephropathy have been well characterized and include arteriosclerosis (75%); fibrous intimal hyperplasia (75%); in three of their patients. Five other reports have documented occlusion of main renal arteries leading to renotubular thyroidization (75%); arteriolar occlusions (68%); TMA (31%), and organizing thrombosis (37%) [49] . vascular hypertension [68] [69] [70] [71] [72] [73] [74] . Most of the patients reported with main renal artery stenosis had had very high Some novel glomerular ultrastructural changes have recently been proposed to be pathognomonic for APS netiters of APAs, but in one case the titers were moderate [64] . The outcome of renovascular hypertension with phropathy [62] . On light microscopy, the silver stains show a combination of glomerular basement membrane APS appears to be good with treatments like anticoagulation, with or without percutaneous balloon angioplasty, wrinkling and reduplication. By electron microscopy, redundant wrinkled segments of basement membrane are leading to recovery of renal function and return to normal blood pressure [68] [69] [70] [71] [72] [73] [74] . The contribution of undiagaccompanied by a "new," straighter thin basement mem-nosed APS in cases of ESRD assumed to be due to pathogenic [84] [85] [86] [87] tic anticoagulation would prevent these events. HowMoreover, the prevalence of lupus anticoagulant was ever, on the strength of the epidemiologic and clinical higher among patients treated by hemodialysis (30%), association of these antibodies, it would appear prudent compared to those treated by conservative (non-dialytic) to incorporate APA testing into the diagnostic evaluaapproach. Subsequently, Sitter, Spannal, and Schiffl retion of recurrent thrombotic episodes on patients receivported that the prevalence of APAs were higher in heing hemodialysis [88-91]. modialysis patients compared to those on continous ambulatory peritoneal dialysis (CAPD) [77] . This higher
APAs IN RENAL TRANSPLANTATION prevalence in hemodialysis has been confirmed by others [78]. Quereda et al in a prospective study of 138 patients
In renal transplant patients, the incidence of APAs may also be increased, even in those without SLE [92] . with nephropathy, found that the prevalence of APAs was higher in patients with SLE (34%) than in those with
In this study of patients without SLE, a prevalence of 28.1% was documented. Patients with and without APAs chronic primary glomerulonephritis (9%) and lowest in patients with non-immunologically mediated renal disdid not differ in age, gender, underlying disease, immunosuppressive regimen, serum creatinine concentration, eases (2.6%) [79] . The origin of APAs in ESRD patients is unclear. It has been postulated that uremia is a form and platelet count. Of these APAs, 65.4% were acquired in the pre-transplant period, while 15.7% acquired APAs of immunodeficiency in which autoimmunity may develop as a result of altered immune function [80] . Some during the post-transplant period. Interestingly, 19 pretransplant APAs disappeared in 52.7% of patients in have suggested that dialysis membranes generate APAs due to incompatibility. In the study by Garcia Morton that series after transplant. The genesis of APAs after renal transplant is unclear. Both pre-transplant and postet al [78] , patients dialyzed with cuprophane membranes had a greater incidence of APAs than those dialyzed transplant APAs were associated with thrombosis affecting the dural, femoral, and transplant veins. against more biocompatible membranes. However, in a larger study by Brunet et al, there was no relationship In the case of SLE patients with APAs in renal transplantation, their survival is worse than those of SLE between the APAs and the type of dialyzer used [80] . Other suggested reasons for generation of APAs in renal transplant patients without APAs [93] . Because of this, Joseph, Radhakrishn, and Appel have suggested ESRD patients include trauma to blood passing through the hemodialysis circuit, as observed in recipients of left that patients with SLE who have APAs require attention in the post-transplant period to detect possible thromventricular assist devices [81] and induction by microbial agents [82] or their products, such as endotoxins present botic events and/or consider prophylactic anticoagulation [94] . Stone, Amend, and Criswell studied the clinical in dialysate. If this were true, one would expect a correlation between prevalence/titers of APAs and length of events in 96 consecutive patients with SLE after renal transplantation [95] . They observed positivity for APAs time on dialysis. Such a relationship has not been shown at this time. Moreover, not all patients exposed to same in 29.1%. Among these, 60% had clinical events related to APAs, including deaths related to APS (10%); deep dialysate develop APAs. Although the precise mechanisms involved in the genesis of APAs in ESRD are venous thrombosis and pulmonary embolism (24%); strokes (16%); renal artery or renal vein thrombosis unknown, they appear to mostly ␤2-GPI-independent [83]· Substantial controversy surrounds the precise risks (16%); and fetal loss (12%) [95] . Although APAs in hepatitis C-positive ESRD patients associated with the presence of APAs in ESRD patients. While some studies suggest that these antibodies are not appear to be non-pathogenic, preliminary data suggest APAs are associated with cytomegalovirus infection in unrelated bone marrow and cord blood allogeneic stem cell transplantation [98] .
Other studies have addressed the impact of APAs renal allograft [107] . This patient lost two renal allografts on renal allograft failure [99] [100] [101] . In one study Wagen in the first month after renal transplantation. The risk Knecht et al reported significantly more APAs in paof early renal allograft loss in patients with ESRD with tients with early renal allograft failure than in patients APAs who received renal transplants without hemodialwith functioning grafts. In that study, 57% final crossysis was 100% in the study of Wagen Knecht et al, sugmatched sera from patients with early nonfunction were gesting a possible protective role for renal allograft positive for 1gG, 1gM, and 1gA APAs [99] . Thus, it is thrombosis by a period of hemodialysis. The reason for possible that testing for APA may identify certain pathe possibly protective effect of a hemodialysis history is tients at risk for allograft failure. Biopsies of these failed unclear, but it is likely that prolonged exposure to heparin allograft kidneys from APA-positive patients showed with hemodialysis may be responsible. Consistent with thrombi in nine patients and infarction in five. However, these observations, in vitro studies show that heparin can these patients also received OK T3 induction therapy, inhibit or neutralize APA binding [108] . Other possible which may have induced renal allograft thrombosis [102] , mechanisms of renal allograft dysfunction in APA-posieven though the same OK T3 indication therapy was tive patients include allograft glomerulonephritis, renal used in patients with functional allografts. Thus, the imvein thrombosis, and post-transplant ARF [109] . pact of immunosuppression in renal allograft thrombosis Unresolved questions include whether patients with must be excluded to better quantify the impact of APAs
APAs with normal renal function should serve as kidney in early allograft failure. However, a role for coagulation donors, in light of possible future renal complications. anomalies, such as factor V Leiden mutation, deficiencies Recently, a case was reported of a patient who developed of protein C and S, as well as lupus anticoagulant in early ARF requiring hemodialysis due to renal artery occlurenal transplant failure, has been suggested by some sion 6 years after donating a kidney to his mother [110] . investigators [99] . Fischereder et al found that throm-ARF in this patient was irreversible, and the patient bophilia represented a 3.5-fold increase in risk for 1-year became dialysis-dependent. renal allograft loss [103] . Although the mechanism for early graft failure in APA-positive patients is unclear, perturbations of hemostasis appear plausible. In an im-MANAGEMENT OF THROMBOSIS IN APS munocytochemical study of failed renal allografts, sigDiagnostic difficulties nificantly more depletion of vascular antithrombin and
It is clear that APS shows substantial heterogeneity increased fibrin deposition were observed by Tory et al in clinical features, as well as the range of autoantibodies. in transplants that failed in the first month than those that Accurate diagnosis is critical because of the high risk failed 2 to 12 months or later after renal transplantation of recurrent thrombosis. This heterogeneity mandates a [104] . No differences in cellular infiltrates were observed, comprehensive approach to laboratory testing [111] [112] [113] [114] , thus excluding cellular rejection. This pattern of allograft as shown in Table 3 . Thus, it is recommended that when loss with fibrin deposition in the absence of cellular infil-APS is suspected, a panel of tests, including lupus anticoagtrates has also been observed in failed cardiac allografts ulant, and anticardiolipin antibody, assays be performed. where depletion of vascular tissue plasminogen activator and endothelial cell activation have been implicated [105, Lupus anticoagulant assays 106]. Wagen Knecht et al provide further proof of the The common denominator of all lupus anticoagulant role of APA in early renal allograft loss in their report of a case in which they isolated APA from a thrombosed tests is that they detect the inhibition of phospholipid-dependent coagulation reactions, thus prolonging coaguof 3.5 offers good protection against recurrences without a major increase in hemorrhages. (abstract; Ruiz-Iraslation times [9] . The term "lupus anticoagulant" is a misnomer, since this phenomenon is not seen exclusively torza G et al, Arthritis Rheum 43:S313, 2000). The factors that trigger recurrent thrombosis are poorly understood in SLE patients. A number of methods have been used to detect the presence of lupus anticoagulant, including [120] . While steroids may decrease APA titers, they do not reduce the risk of thrombosis. Recently, it has been modifications of the activated partial thromboplastin times (aPTT), the kaolin cephalin clotting time (KCT),
shown that steroids may also potentiate the anticoagulant effect of warfarin [121] . Scattered case reports sugthe dilute Russell viper venom time (dRVVT), and the thromboplastin inhibition test (TTI). The dRVVT is congest that plasmapheresis is beneficial in APS patients presenting with TMA [122, 123] . It should also definitely sidered to be one of the most sensitive tests for lupus anticoagulant.
be considered in the patients presenting with CAPS, as it removes the pathogenic APAs, inducing the widespread Tests for anticardiolipin antibodies thrombotic diathesis. The role of thrombolytics is unclear at this time, although thrombolytic therapy improved Most patients with APS are identified with elevated anticardiolipin antibodies. The precursor for this assay, outcome in one patient with acute large-vessel occlusive disease [124] . The role of hydroxycholoroquine and/or the biologic false positive test for syphilis developed at the Venereal Disease Research Laboratory, is itself an chloroquine in preventing thrombosis in APS is controversial. Some data suggest that these drugs have antianticardiolipin test in which cardiolipin is the antigen. High levels of anticardiolipin antibodies are predictive thrombotic actions. Platelet aggregation induced by adenosine diphosphate (ADP), collagen, and ristocetin can of an increased risk of thrombosis [8] . It should be emphasized that positive anticardiolipin antibodies assays be inhibited by chloroquine in a dose-dependent manner [125] [126] [127] . Consistent with these observations, hydromay be found in the asymptomatic "normal" population with a prevalence that varies from 3 to 10% [8] . It should xychloroquine significantly diminished both thrombus size and total time of thrombus formation in mice with APS also be appreciated that in some cases of APA positivity in patients with renal disease, such as in acute post- [128] . However, the effect of chloroquine in APS in humans is unclear. Experience with intravenous immunostreptococcal glomerulonephritis, the presence of APAs may be a marginal immunological phenomenon trigglobulins in treating APS is limited and uncontrolled. Some data suggest that it is effective for the prevention gered by streptococcal infection, unrelated to the glomerular disease [115] . Other anticardiolipin tests include of recurrent pregnancy loss when therapies such as heparin and low-dose aspirin have failed [128] [129] [130] [131] . Its role antibodies against ␤2-GP1, the major protein cofactor for APAs, and antibodies against phosphatidyl ethanolin treating renal disease in APS is unknown at this time, although intravenous immunoglobulin in combination amine. Enzyme-linked immunosorbent assays (ELISAs) for ␤2-GP1 antibodies are considered to be more specific, with steroids and heparin improves survival in CAPS. Recently, we showed that immunoglobulin decreases in but less sensitive for APS than anticardiolipin assays [111] . Clinical correlation is therefore necessary to devivo thrombosis and endothelial cell activation in animal models of APS [131, 132] . Newer therapeutic modalities cide the significance of a positive APA test. This comprehensive diagnostic approach ( Table 3 ) often includes that deserve further investigation include prostacyclin, fibronolytic agents such as tissue plasminogen activator using a combination of coagulation-based tests for lupus anticoagulant and solid-phase ELISAs for anticardio-(TPA) and defibrotid. Some investigators have shown that tolerance can be induced to experimental APS by lipin antibodies. Such an approach would help resolve the "equivocal" cases of APS [116, 117] .
syngeneic stem cell transplantation [132] . 
